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To the editors: 
 
We read with interest the report of Kristen et al., wherein the prognostic utility of histologic 
‘amyloid load’ quantification by endomyocardial biopsy was described.(1) While the authors 
state that no significant variation was observed between biopsy sites, this observation was not 
quantified. Our collective experience is that Congo red staining of different biopsy specimens 
from within the same organ in the same patient can vary greatly in so called ‘amyloid load’, 
reflecting the patchy nature of amyloid deposition which is well described,(ref) and  introduces 
the likelihood  of sampling error.  Furthermore, quantification of amyloid load from a single 
slide does not control for variation in sample size, as a true load would require normalization to 
total heart size determined by myocardial mass.  In addition, immunohistochemistry in AL 
amyloidosis is associated with both ‘false negative’ and considerable background ‘non-specific’ 
staining calling into question the accuracy of quantification of amyloid burden by the method 
decribed.  As the authors found no survival advantage with chemotherapy in AL amyloidosis in 
the context of higher levels of amyloid load (>20%), we are concerned that clinicians may 
choose to withhold life extending chemotherapy treatment from patients with advanced 
cardiac AL amyloidosis because of perceived futility, when it remains clear that some such 
patients do undoubtedly benefit from it.  Cardiac MR with extra cellular volume (ECV) 
determination is an attractive non-invasive modality through which to quantify amyloid burden 
because the entire heart is imaged, yielding a truer average that has been shown to strongly 
correlate to cardiac specific biomarkers such as NT-proBNP.(2) Importantly, CMR with ECV 
measurement also lends itself readily to repeat measurements, has none of the attendant risks 
of an invasive procedure, and is likely to afford a more sensitive means to follow amyloid 
regression with treatment.(ref abstract from ISA). We agree with the authors that precursor 
protein identification is an essential step in management of cardiac amyloid patients, and that 
endomyocardial biopsy has a definite role both in diagnosis and typing of cardiac amyloid. We 
would strongly suggest that caution must be exercised however, when making management 
decisions based upon quantification of amyloid from a histological specimen.  
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